SMALL_CELL_LUNG_CÁNCER . Dr. Jacob Sands del Dana-Farber Cancer Institute Repasa la I+D Qué Avanza Hacia el Mercado y una de Sus Apuestas es por TARLATAMAB BY AMGEN ... Estamos Viendo un Subconjunto de Personas Que Obtienen Resultados Extraordinarios y Control de la Enfermedad a Largo Plazo con este Medicamento .

 

DR. LUIS PAZ ARES : " ES EL NACIMIENTO DE UNA NUEVA TERAPIA ”.  TARLATAMAB TIENE EL POTENCIAL DE CAMBIAR EL MANEJO CLÍNICO DEL CÁNCER RECURRENTE/REFRACTARIO ( SEGUNDA LÍNEA ) Y MEJORAR LA SUPERVIVENCIA EN UN AÑO DE LOS PACIENTES CON SMALL_CELL_LUNG_CANCER .

DLL3-Targeted Drugs .

The Most Movel Therapies Right Now Are Those That Target DLL3 . 

DLL3 IS a Receptor on The Surface of Many SMALL CELL LUNG CANCERS . 

The Study That is Furthest Along As of The End of 2023 is a Drug Called TARLATAMAB, Which Binds DLL3 and Immune Cells Together, Creating an Immune Response that Enables The Immune System To Attack And Kill The Cáncer Cells . Like Other Immunotherapies, We’re Seeing a Subset of Individuals That Have Extraordinary Outcomes and Long-Term Disease Control With This Drug . 

There Are Other Drugs in This Class in Addition To TARLATAMAB That Also Bind The Cáncer Cells And Immune Cells Together .  

Antibody Drug Conjugates (ADCs) .

Other Drugs Now Being Developed Have a Different Target For The Immune Cell .

 They Bring in a Different Kind of Cell From The Immune System Along With the Cáncer Cell to Create an Immune Response .  

These Drugs Are Called Antibody Drug Conjugates (ADCs) .

 These Drugs Bind To a Receptor on The Surface of The Cáncer Cell And Release The Chemotherapy Inside The Cell . It’s kind of Like a Targeted Chemotherapy And There Are Now Múltiple Different Receptors That Are Being Utilized in This Way .

 We Are Essentially Accessing “ DOORS ” To SCLC To Be Able To Deliver Chemotherapy Into The Cells . ...